Potential Role of Anti-Complement Agents in the Treatment of COVID-19-Related ARDS

Mediterranean Journal of Rheumatology

ARTICLE

Christina Spanopoulou¹  Dimitrios Kassimos²  Dimitrios Cassimos³ 

[1] Department of Internal Medicine, General Hospital of Amaliada;Rheumatology Clinic, 401 General Military Hospital of Athens;Paediatric Clinic, General University Hospital of Alexandroupolis

关键词: anti-C5a;    COVID-19;    ARDS;    complement system;    cytokine storm;   

DOI  :  10.31138/mjr.31.3.304

学科分类：社会科学、人文和艺术（综合）

来源: PCO Convin S.A.

【 摘 要 】

The current COVID-19 pandemic has caused hundreds of thousands of deaths with fatality figures continuing to rise. Lung injury has been the leading cause of mortality with nearly 90% of deaths resulting from ARDS. This condition is a serious immunological complication, characterised by widespread lung inflammation causing severe hypoxaemia, refractory to oxygen treatment. To date, no pharmacological treatment has been approved for the management of ARDS. So far, mechanical ventilation with the application of positive end-expiratory pressure (PEEP) has been the standard of care.

【 授权许可】

CC BY-NC